| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Managing with Variations in Measures |
|
Advice You - Managing with Variations in Measures
Though measuring results and procedures is extremely important to the proper functioning of any business, there is a pro According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product blem presented by the common habit of managers to focus on only the most recent results that have been achieved, instead ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in of patterns and trends that explain outcomes over time. There is a great deal of risk involved in centering on only on t lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. he most recent measures that have been obtained. This risk is easy to recognize by anybody who has had to work with sta here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe istical process control, as there are always occurrences of error and sudden variation. These errors and variations are d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro the result of having applied a measurement system to the same single item over and over and obtaining different results. ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc Consider testing the acidity level of water, or the voltage of a wire several times in a row, and receiving different easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi eadings every time. The same goes for business management. From improvement and quality strategies such as Six Sigma, nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically anagers and other businesspeople can learn to accept the latest measures and results only as the latest piece of a patte and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ rn or trend. This allows them to determine the true successes and failures in their business, and put emphasis upon wha ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi needs to be done in the future to match or improve upon the effectiveness of their past actions. By applying control a ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a d running charts in order to put the date from their measures in context, discussions can be concentrated on improving p dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod rocesses, rather than just the end product. The benefit of examining processes through trends and patterns, such as is cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin one with Six Sigma business strategies, is that it becomes much easier to accurately pinpoint strengths and weaknesses w tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen thin a business. By concentrating on the latest data only, a manager runs the risk of placing too much emphasis on a st t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel atistical error, or a simple exception in the type results were achieved. This means that an entire business effort or ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust trategy could risk being altered due to a misinterpretation of the way that company is functioning. By looking at past y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products erformances as well, managers are empowered with more of a “whole” view of the functions of the organization, and can de . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de termine how successes may be easier and more effectively achieved in the future. Properly done, the result of well anal elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip zed statistical patterns and trends will almost always be improved processes and therefore greater business achievements tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Best Laid Plans - Unexpected Events - and the Choices we Have
|